New combo therapy aims to shrink inoperable skin cancers
NCT ID NCT05574101
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining radiation therapy with the immunotherapy drug cemiplimab can effectively treat locally advanced skin cancer that cannot be surgically removed. The study involves 34 participants who will receive both treatments over about 12 months. The main goal is to see how long the cancer stays under control after treatment starts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemiplimab (immunotherapy drug) and radiation therapy
What this could lead to
If successful, this combination could offer a new, non-surgical treatment option for people with advanced skin cancer that cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial with only 34 participants. It is not yet proven to work better than existing treatments, and immunotherapy can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic (Data Collection Only)
Cleveland, Ohio, 44195, United States
-
Fox Chase Cancer Center (Data Collection Only)
Philadelphia, Pennsylvania, 19111, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Memorial Sloan Kettering Bergen (All protocol activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center at Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All protocol activities)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
-
Moffitt Cancer Center (Data Collection Only)
Tampa, Florida, 33612, United States
-
University of Colorado (Data Collection Only)
Aurora, Colorado, 80045, United States
-
University of Washington (Data Collection Only)
Seattle, Washington, 98109, United States